This Chinese expert consensus provides standardized recommendations for the clinical application of finerenone in older patients with cardiorenal and metabolic comorbidities, emphasizing its efficacy and safety profile.
Answers are grounded in this paper and cite their sources.
Supports finerenone integration into geriatric cardiorenal care; extends RAAS/MR evidence into standardized expert consensus.
Dysregulation of the renin‐angiotensin‐aldosterone system (RAAS) constitutes a pivotal factor in the onset and progression of various geriatric diseases, including cardiovascular diseases, diabetes, and chronic kidney disease (CKD), all closely linked to adverse cardiorenal outcomes in older patients. Excessive activation of the mineralocorticoid receptor (MR) drives inflammation, fibrosis, and oxidative stress across tissues and organs, representing a fundamental mechanism underlying systemic metabolic disorders, diabetes, cardiovascular diseases, and kidney pathologies. Emerging clinical evidence indicates that the non‐steroidal mineralocorticoid receptor antagonist (ns‐MRA) finerenone can block MR with high selectivity, significantly reducing cardiorenal event risks in older patients and thereby enhancing overall health status. This offers a novel therapeutic avenue for the long‐term management of older patients burdened with multiple chronic comorbidities.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a review in Geriatric comorbidities (Chronic Kidney Disease, Heart Failure, Hypertension, Diabetes). Finerenone was evaluated. Finerenone is recommended for older patients with chronic kidney disease, heart failure, and hypertension to block mineralocorticoid receptor overactivation and reduce cardiorenal risks.
Synapse has enriched 10 related papers. Consider them for comparative context: